EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Diagnosis to Individualized Therapies in Rare Genetic Diseases: New Approach Methodologies, RNA Therapeutics, and the Case for a Human-First Filter

Saeed Anwar iD, Toshifumi Yokota

Genes · 2026

DOI: 10.3390/genes17070780 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2026. Verfasst von Saeed Anwar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Rare Diseases, Genetic Diseases, Inborn, Precision Medicine, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Advanced Education and Technology, Alberta Innovates Health Solutions, Canada Foundation for Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rare genetic diseases are heterogeneous across mechanisms, trajectories, and treatment responses. To date, approved therapies remain available for only a small proportion of rare genetic diseases. Oligonucleotide-based RNA therapeutics, particularly antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), offer a promising therapeutic avenue for rare genetic diseases with sequence-level precision. However, traditional preclinical paths may mis-predict human outcomes when disease biology diverges from animal models. New approach methodologies (NAMs), including patient-derived induced pluripotent stem cells (iPSCs), organoid models, and clinical-trials-in-a-dish (CTiD), aim to bring human biology earlier into the translational pipeline. NAMs enable variant-to-function studies, efficacy screening, and safety triage at clinically relevant speed and scale. While critics argue that NAMs are unvalidated and cannot replace preclinical animal models, proponents report that they are increasingly able to recapitulate human phenotypes and predict clinical liabilities, although their predictive validity remains context-dependent. Here, a front-loaded human filter refers to the use of human-derived systems early in development to support mechanistic interpretation, candidate prioritization, and early liability assessment before broader nonclinical evaluation. Recent studies pairing NAMs with ASOs support rapid, patient-specific preclinical screening in selected settings, while also showing the need for broader evidence on delivery, pharmacology, safety, and clinical relevance. This review places these developments within the translational realities of oligonucleotide-based therapeutics, including model fidelity, ASO chemistry and optimization, delivery challenges, pharmacology, regulatory pathways for individualized ASOs, and accessibility. We also propose a pragmatic validation framework to assess the scientific and translational credibility of NAMs across rare genetic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesGenetic Diseases, InbornPrecision MedicineGenetic TherapyMolecular Diagnostic TechniquesHumansOligonucleotides, AntisenseAnimalsRNA, Small InterferingInduced Pluripotent Stem Cells

Stichwörter der Autor:innen

RNA therapeuticsantisense oligonucleotides (ASOs)clinical-trials-in-a-dish (CTiD)engineered tissuesinduced pluripotent stem cells (iPSCs)microphysiological systemsnew approach methodologies (NAMs)pharmacokinetics/pharmacodynamics (PK/PD)rare genetic diseasessmall interfering RNAs (siRNAs)

Substanzen

Oligonucleotides, AntisenseRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
  • Neuroscience and Mental Health Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada.
  • Cardiovascular Research Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 1C9, Canada.
  • Women and Children's Health Research Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 1C9, Canada.
  • The Friends of Garrett Cumming Research and Muscular Dystrophy Canada Endowed Research, University of Alberta, Edmonton, AB T6G 2H7, Canada.

ORCID-Profile: Saeed Anwar

Förderung

  • Alberta Advanced Education and Technology
  • Alberta Innovates Health Solutions
  • Canada Foundation for Innovation
  • Canadian Institutes of Health Research
  • Friends of FSH Research
  • Friends of Garrett Cumming Research Chair Fund
  • Henri M. Toupin Chair Neurological Science Research Chair Fund
  • FSH Society

Zitieren

APA

Anwar, S., & Yokota, T. (2026). Molecular Diagnosis to Individualized Therapies in Rare Genetic Diseases: New Approach Methodologies, RNA Therapeutics, and the Case for a Human-First Filter. Genes. https://doi.org/10.3390/genes17070780

Vancouver

Anwar S, Yokota T. Molecular Diagnosis to Individualized Therapies in Rare Genetic Diseases: New Approach Methodologies, RNA Therapeutics, and the Case for a Human-First Filter. Genes. 2026. doi:10.3390/genes17070780

BibTeX
@article{Anwar2026,
  author = {Anwar, Saeed and Yokota, Toshifumi},
  title = {Molecular Diagnosis to Individualized Therapies in Rare Genetic Diseases: New Approach Methodologies, RNA Therapeutics, and the Case for a Human-First Filter},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17070780}
}
Kostenlos starten →